Jesus Ramirez, MD
Pulmonary Disease · Panama City, FLNPI 1871522201
Payments from drug & device makers
Across 491 payments — averaging $69.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apria Healthcare LLC$24K
- GSK$3K
- Inspire Medical Systems, Inc.$2K
- AstraZeneca$2K
- Boehringer Ingelheim$796
- Philips North America LLC$663
- plus $2K from 22 others
What the payments were for
- Speaking & faculty fees$24,19071%
- Food & beverage$9,79629%
- Education$1060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apria Healthcare LLC | 18 | $24,190 |
| GSK | 171 | $2,931 |
| Inspire Medical Systems, Inc. | 62 | $1,713 |
| AstraZeneca | 79 | $1,599 |
| Boehringer Ingelheim | 40 | $796 |
| Philips North America LLC | 20 | $663 |
| Sanofi | 14 | $474 |
| Grifols USA, LLC | 15 | $279 |
| Verona Pharma, Inc. | 11 | $193 |
| Insmed, Inc. | 7 | $174 |
| United Therapeutics Corporation | 3 | $164 |
| Actelion Pharmaceuticals US, Inc. | 4 | $148 |
| Regeneron Healthcare Solutions, Inc. | 9 | $148 |
| Viatris Specialty LLC | 14 | $147 |
| Mylan Specialty L.p. | 6 | $135 |
| Jazz Pharmaceuticals Inc. | 3 | $73 |
| 3b Medical, Inc. | 1 | $43 |
| AbbVie(2 entities) | 3 | $38 |
| Fisher & Paykel Healthcare Inc | 2 | $31 |
| Amgen | 1 | $22 |
| Baxter Healthcare | 1 | $21 |
| Merck | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Gilead | 1 | $16 |
| Olympus America Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
| Medtronic | 1 | $14 |
| Intuitive Surgical | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Resmed$24,190
- DUPIXENT$250
- BEVESPI AEROSPHERE$141
- FARXIGA$141
- Inspire Upper Airway Stimulation System$128
- TRELEGY ELLIPTA$100
How this compares
$34,092 in reported general payments places this provider in the 80th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 510 | $627,060 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 36 | $417,346 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 193 | $192,751 |
| OpsumitMacitentan | 11 | $136,218 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 112 | $86,457 |
| Breo ElliptaFluticasone/Vilanterol | 71 | $43,831 |
| Spiriva RespimatTiotropium Bromide | 41 | $35,673 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 36 | $34,731 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 36 | $27,845 |
| SymbicortBudesonide/Formoterol Fumarate | 68 | $24,605 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 551 | $24,551 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 65 | $14,571 |
| Ventolin HfaAlbuterol Sulfate | 136 | $12,166 |
| Wixela InhubFluticasone Propion/Salmeterol | 46 | $6,221 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $5,939 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $2,931 | $763,287706 claims |
| Grifols USA, LLCProlastin C | $279 | $417,34636 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,599 | $217,356261 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $148 | $136,21811 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $796 | $98,249113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Panama City
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.